Enlivex (ENLV) vs Pulmatrix (PULM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulmatrix is the larger company by market cap ($5.3 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | PULM |
|---|---|---|
| Share price | $0.254 | $1.46 |
| Market cap | $5.06M | $5.33M |
| 1-day change | -8.30% | -4.39% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $5.24 |
| 52-week low | $0.224 | $1.16 |
| Distance from 52-week high | -99.06% | -72.11% |
| Analyst consensus | none | — |
| Avg. price target upside | +31396.06% | — |
| Average volume | 945.30K | 24.09K |
| Shares outstanding | 19.91M | 3.65M |
| Employees | 34 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ENLV vs PULM FAQ
Which is bigger, Enlivex or Pulmatrix?
Pulmatrix (PULM) is larger, with a market capitalization of $5.33M compared with $5.06M for Enlivex (ENLV).
Are Enlivex and Pulmatrix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.